228 related articles for article (PubMed ID: 9206879)
1. [The intravesical administration of BCG vaccine in treating recurrent superficial bladder cancer].
Panteleeva ES; Neprina GS; Vatin OE; Kariakin OB; Safiullin KN
Urol Nefrol (Mosk); 1997; (2):29-32. PubMed ID: 9206879
[TBL] [Abstract][Full Text] [Related]
2. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
3. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
4. [Intravesical bacillus Calmette-Guerin in the treatment of recurrent superficial bladder tumors].
Nakano M; Iwamuro S; Fujii H; Kondoh I
Hinyokika Kiyo; 1988 Jun; 34(6):983-6. PubMed ID: 3223463
[TBL] [Abstract][Full Text] [Related]
5. [Intravesical BCG therapy for superficial bladder cancer].
Segawa N; Iwamoto Y; Azuma H; Yamamoto K; Ueda H; Katsuoka Y
Hinyokika Kiyo; 1998 Sep; 44(9):627-31. PubMed ID: 9805666
[TBL] [Abstract][Full Text] [Related]
6. [Intravesical BCG therapy in patients with recurrent superficial bladder tumors].
Sugimoto M; Yamamoto H; Itakura H; Shinohara M; Kinoshita K
Gan To Kagaku Ryoho; 1989 Dec; 16(12):3725-8. PubMed ID: 2596855
[TBL] [Abstract][Full Text] [Related]
7. [Results obtained by intravesical instillation of BCG in superficial bladder tumors].
Romics I; Dietmar B; Christoph R
Orv Hetil; 1990 Jan; 131(1):25-8. PubMed ID: 2405331
[TBL] [Abstract][Full Text] [Related]
8. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
9. [Adjuvant local BCG-immunotherapy in patients with urothel cancer of the bladder (author's transl)].
Flamm J; Grof F
Wien Med Wochenschr; 1981 Oct; 131(20):501-6. PubMed ID: 7314632
[TBL] [Abstract][Full Text] [Related]
10. [Effect of prophylactic intravesical instillation of BCG for superficial bladder cancer].
Segawa N; Inamoto T; Nomi H; Ibuki N; Azuma H; Katsuoka Y
Hinyokika Kiyo; 2009 Apr; 55(4):175-80. PubMed ID: 19462820
[TBL] [Abstract][Full Text] [Related]
11. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
Steinbach F; Schuster F
Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
13. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
Pham HT; Soloway MS
Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
[TBL] [Abstract][Full Text] [Related]
14. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
[TBL] [Abstract][Full Text] [Related]
15. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of PT1 tumors of the bladder using transurethral resection and intravesical immunotherapy].
Bertault D; Benoit G; Vieillefond A; Ribaud P; Bensadoun H; Jardin A
Ann Urol (Paris); 1990; 24(2):97-101; discussion 102. PubMed ID: 2350169
[TBL] [Abstract][Full Text] [Related]
17. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
[TBL] [Abstract][Full Text] [Related]
18. [Changes in the activity of natural killer cells in superficial bladder cancer during intravesical BCG therapy].
Samodai L; Dankó K
Orv Hetil; 1992 Sep; 133(36):2283-6, 2291-2. PubMed ID: 1408062
[TBL] [Abstract][Full Text] [Related]
19. Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.
Zlotta A; Drowart A; van Vooren JP; Simon J; Schulman CC; Huygen K
Acta Urol Belg; 1994 Sep; 62(3):63-8. PubMed ID: 7976857
[TBL] [Abstract][Full Text] [Related]
20. [Repeated yearly BCG treatment in superficial bladder cancer].
Somogyi L; Török A; Bors G; Drinóczy M; Horváth R
Orv Hetil; 1989 Mar; 130(13):671-3. PubMed ID: 2726237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
